May 11, 2026 4:23 pm EDT SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
Mar 31, 2026 6:40 am EDT SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Mar 4, 2026 4:20 pm EST SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
Feb 26, 2026 8:23 am EST SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
Jan 28, 2026 8:00 am EST SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
Jan 21, 2026 8:00 am EST SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
Dec 22, 2025 8:00 am EST SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
